ABUS Arbutus Biopharma Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: ABUS

Price (delayed)

$2.72

Market cap

$488.22M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.44

Enterprise value

$463.7M

Arbutus Biopharma Corporation is a biopharmaceutical company primarily dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple ...

Highlights
The debt has declined by 19% year-on-year and by 7% since the previous quarter
The company's EPS rose by 4.3% QoQ and by 4.3% YoY
ABUS's quick ratio is up by 26% YoY but it is down by 7% QoQ
Arbutus Biopharma's net income has decreased by 4.9% YoY but it has increased by 3.5% from the previous quarter
Arbutus Biopharma's gross profit has shrunk by 54% YoY and by 18% QoQ
Arbutus Biopharma's revenue has shrunk by 54% YoY and by 18% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://arbutusbio.com
Peers: NWBO

Key stats

What are the main financial stats of ABUS
Market
Shares outstanding
179.49M
Market cap
$488.22M
Enterprise value
$463.7M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.3
Price to sales (P/S)
24.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
25.56
Earnings
Revenue
$18.14M
EBIT
-$72.39M
EBITDA
-$70.99M
Free cash flow
-$86.92M
Per share
EPS
-$0.44
Free cash flow per share
-$0.52
Book value per share
$0.63
Revenue per share
$0.11
TBVPS
$0.87
Balance sheet
Total assets
$144.4M
Total liabilities
$38.38M
Debt
$1.77M
Equity
$106.02M
Working capital
$109.54M
Liquidity
Debt to equity
0.02
Current ratio
5.87
Quick ratio
5.68
Net debt/EBITDA
0.35
Margins
EBITDA margin
-391.3%
Gross margin
100%
Net margin
-401.6%
Operating margin
-430.2%
Efficiency
Return on assets
-43.4%
Return on equity
-57.8%
Return on invested capital
-61.2%
Return on capital employed
-59.4%
Return on sales
-399%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ABUS stock price

How has the Arbutus Biopharma stock price performed over time
Intraday
-0.37%
1 week
-6.53%
1 month
8.8%
1 year
-9.33%
YTD
8.8%
QTD
5.43%

Financial performance

How have Arbutus Biopharma's revenue and profit performed over time
Revenue
$18.14M
Gross profit
$18.14M
Operating income
-$78.03M
Net income
-$72.85M
Gross margin
100%
Net margin
-401.6%
ABUS's operating margin has dropped by 166% year-on-year and by 22% since the previous quarter
The net margin has dropped by 126% year-on-year and by 18% since the previous quarter
Arbutus Biopharma's gross profit has shrunk by 54% YoY and by 18% QoQ
Arbutus Biopharma's revenue has shrunk by 54% YoY and by 18% QoQ

Growth

What is Arbutus Biopharma's growth rate over time

Valuation

What is Arbutus Biopharma stock price valuation
P/E
N/A
P/B
4.3
P/S
24.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
25.56
The company's EPS rose by 4.3% QoQ and by 4.3% YoY
ABUS's price to book (P/B) is 72% higher than its 5-year quarterly average of 2.5 and 30% higher than its last 4 quarters average of 3.3
Arbutus Biopharma's equity has decreased by 23% YoY and by 11% QoQ
Arbutus Biopharma's revenue has shrunk by 54% YoY and by 18% QoQ
The price to sales (P/S) is 44% higher than the last 4 quarters average of 17.3 and 5% higher than the 5-year quarterly average of 23.6

Efficiency

How efficient is Arbutus Biopharma business performance
The company's return on sales has shrunk by 146% YoY and by 19% QoQ
The ROIC has declined by 34% year-on-year and by 4.3% since the previous quarter
Arbutus Biopharma's return on assets has decreased by 33% YoY and by 3.8% QoQ
The ROE is down by 25% year-on-year and by 2.5% since the previous quarter

Dividends

What is ABUS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ABUS.

Financial health

How did Arbutus Biopharma financials performed over time
ABUS's total liabilities is down by 34% year-on-year and by 2.3% since the previous quarter
The company's current ratio rose by 28% YoY but it fell by 7% QoQ
The debt is 98% smaller than the equity
Arbutus Biopharma's equity has decreased by 23% YoY and by 11% QoQ
The debt has declined by 19% year-on-year and by 7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.